A Replication-Selective Adenoviral Vector for Head and Neck Cancers | Clinical Pharmacy and Pharmacology | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Kirn  DHMcCormick  F Replicating viruses as selective cancer therapeutics.  Mol Med Today 1996;2519- 527PubMedGoogle ScholarCrossref
Heise  CKirn  DH Replication-selective adenoviruses as oncolytic agents.  J Clin Invest 2000;105847- 851PubMedGoogle ScholarCrossref
Webb  HESmith  CE Viruses in the treatment of cancer.  Lancet 1970;11206- 1208PubMedGoogle ScholarCrossref
Shisler  JDuerksen-Hughes  PHermiston  TMWold  WSGooding  LR Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis.  J Virol 1996;7068- 77PubMedGoogle Scholar
Chan  GBoyle  JOYang  EK  et al.  Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.  Cancer Res 1999;59991- 994PubMedGoogle Scholar
Shirakawa  THamada  KZhang  Z  et al.  A Cox-2 promoter-based replication-selective adenoviral vector to target the Cox-2–expressing human bladder cancer cells.  Clin Cancer Res 2004;104342- 4348PubMedGoogle ScholarCrossref
Zhou  LX Biological behavior of hypopharyngeal carcinoma.  Nippon Jibiinkoka Gakkai Kaiho 1997;10059- 67PubMedGoogle ScholarCrossref
Graham  FL Growth of 293 cells in suspension culture.  J Gen Virol 1987;68937- 940PubMedGoogle ScholarCrossref
McKinnon  RDBacchetti  SGraham  FL Tn5 mutagenesis of the transforming genes of human adenovirus type 5.  Gene 1982;1933- 42PubMedGoogle ScholarCrossref
McGrory  WJBautista  DSGraham  FL A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5.  Virology 1988;163614- 617PubMedGoogle ScholarCrossref
Bett  AJHaddara  WPrevec  LGraham  FL An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3.  Proc Natl Acad Sci U S A 1994;918802- 8806PubMedGoogle ScholarCrossref
Graham  FLvan der Eb  AJ A new technique for the assay of infectivity of human adenovirus 5 DNA.  Virology 1973;52456- 467PubMedGoogle ScholarCrossref
Graham  FLPrevec  L Manipulation of Adenovirus Vectors. Vol 7. Clifton, NJ: Human Press Inc; 1991:109-128
Yajima  TYagihashi  AKameshima  H  et al.  Quantitative reverse transcription–PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system.  Clin Chem 1998;442441- 2445PubMedGoogle Scholar
Bergelson  JMCunningham  JADroguett  G  et al.  Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5.  Science 1997;2751320- 1323PubMedGoogle ScholarCrossref
Tomko  RPXu  RPhilipson  L HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses.  Proc Natl Acad Sci U S A 1997;943352- 3356PubMedGoogle ScholarCrossref
Huebner  RJRowe  WPSchatten  WESmith  RRThomas  LB Studies on the use of viruses in the treatment of carcinoma of the cervix.  Cancer 1956;91211- 1218PubMedGoogle ScholarCrossref
Nemunaitis  JKhuri  FGanly  I  et al.  Phase II trial of intratumoral administration of ONYK-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.  J Clin Oncol 2001;19289- 298PubMedGoogle Scholar
Whyte  PBuchkovich  KJHorowith  JM  et al.  Association between an oncogene and anti-oncogene: the adenovirus E1A proteins bind to retinoblastoma gene product.  Nature 1988;334124- 129PubMedGoogle ScholarCrossref
Rodriguez  RSchuur  ERLim  HYHenderson  GASimons  JWHenderson  DR Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.  Cancer Res 1997;572559- 2563PubMedGoogle Scholar
Adachi  YReynolds  PNYamamoto  M  et al.  A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging.  Cancer Res 2001;617882- 7888PubMedGoogle Scholar
Scioscia  KASnyderman  CHRueger  R  et al.  Role of arachidonic acid metabolism in tumor growth inhibition by nonsteroidal anti-inflammatory drugs.  Am J Otolaryngol 1997;181- 8PubMedGoogle ScholarCrossref
Freimuth  P A human cell line selected for resistance to adenovirus infection has reduced levels of the virus receptor.  J Virol 1996;704081- 4085PubMedGoogle Scholar
Turturro  FSeth  PLink  CJ  Jr In vitro adenoviral vector p53–mediated transduction and killing correlates with expression of Coxsackie-adenovirus receptor and ανβ5 integrin in SUDHL-1 cells derived from anaplastic large-cell lymphoma.  Clin Cancer Res 2000;6185- 192PubMedGoogle Scholar
Li  DDuan  LFreimuth  PO’Malley  BW  Jr Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer.  Clin Cancer Res 1999;54175- 4181PubMedGoogle Scholar
Original Article
July 2005

A Replication-Selective Adenoviral Vector for Head and Neck Cancers

Arch Otolaryngol Head Neck Surg. 2005;131(7):630-634. doi:10.1001/archotol.131.7.630

Objective  To test the oncolytic activity of cyclo-oxygenase 2 (COX-2) promoter–based conditional replication-selective adenovirus vector for squamous cell carcinoma cells of the head and neck.

Design  In vitro study.

Subjects  None.

Interventions  A conditional replication-selective adenovirus vector in which the expression of E1a, required for viral replication, is controlled by the COX-2 promoter, Ad-COX2-E1a, was generated. Its oncolytic activity according to the levels of COX-2 and of Coxsackie and adenovirus receptor expression was tested in a series of human head and neck squamous cell carcinoma cell lines.

Results  The respective COX-2 messenger RNA expression ratios of KB, H891, T891, T892, and L871 were 1.5, 60.0, 1.0, 14.6, and 1.3. The corresponding Coxsackie and adenovirus receptor messenger RNA expression ratios were 1, 1, 5, 3, and 1. In vitro assays showed significant growth suppression of cancer cell lines with strong expressions of COX-2.

Conclusion  This study demonstrated the possibility of oncolytic therapy using the COX-2 promoter–based conditional replication-selective adenovirus for head and neck squamous cell carcinoma expressing COX-2.